ALXO - ALX Oncology climbs on updated results for ALX148 in early-stage gastric cancer trial

peterschreiber.media/iStock via Getty Images ALX Oncology ([[ALXO]] +13.6%) has risen more than a tenth after announcing updated clinical data from its ongoing ASPEN-01 trial, which indicated more than 70% of objective response rate ((ORR)) for ALX148 as a combination therapy in gastric or gastroesophageal junction cancer. The Phase 1b study was designed to evaluate ALX148 in combination with trastuzumab and chemotherapy. The results as of data cut-off of May 3, 2021, were presented at the 23rd World Congress on Gastrointestinal Cancer showing the outcome after dosing 18 patients with 10 mg/kg or 15 mg/kg of ALX148. The new results indicate that “ALX148 in combination with trastuzumab and chemotherapy is highly active and well-tolerated in patients with second-line or greater (“>2L”) HER2 positive GC [abstract SO-31],” the company said. In patients with >2L HER2 positive GC, ALX148 has led to 72% ORR and an estimated overall survival (“OS”) of 76% at 12 months

For further details see:

ALX Oncology climbs on updated results for ALX148 in early-stage gastric cancer trial